Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 328 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies MOST POPULAR A Daily Survival Kit for Serious Illness September 8, 2021 Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 Findings from a Population-Based Study on Cancers Associated with Alcohol Consumption July 28, 2021 GreaterGood’s Mask Donations Are Helping Wildlife Sanctuaries Continue Their Essential Work September 10, 2020 Load more HOT NEWS Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in... Study Shows 4 Drugs Better Than 3 for Women with HER2-Positive... Kid Friendly Meals Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas
